A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
The purpose of this Phase 3 study is to determine whether an investigational drug called KSI-301 is safe and effective in the treatment of macular edema secondary to retinal vein occlusion, compared with the standard treatment aflibercept.
The standard treatment for macular edema secondary to vein occlusion involves eye injections every month to decrease the swelling of the retina. These injections work by blocking a protein in the eye called vascular endothelial growth factor (VEGF). When there is too much VEGF inside the eye because of retinal vein occlusion, swelling can occur. KSI-301, developed by Kodiak Sciences Inc., is designed to decrease the fluid leakage and swelling in the retina by blocking VEGF. KSI-301 may last longer in the eye compared to the standard injection treatments(i.e., aflibercept) and thus requiring fewer injections over time for patients.
In this study, the standard dose of KSI-301 will be compared to the standard dose of aflibercept. Participants are randomly assigned to receive either KSI-301 or aflibercept. There are equal number of patients in each arm of the study.
To learn more details about this study, please click on the link at the top of this page which will take you to www.clinicaltrials.gov.